RNAi-Based Functional Profiling of Loci from Blood Lipid Genome-Wide Association Studies Identifies Genes with Cholesterol-Regulatory Function.

Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany
PLoS Genetics (Impact Factor: 8.17). 02/2013; 9(2):e1003338. DOI: 10.1371/journal.pgen.1003338
Source: PubMed

ABSTRACT Genome-wide association studies (GWAS) are powerful tools to unravel genomic loci associated with common traits and complex human disease. However, GWAS only rarely reveal information on the exact genetic elements and pathogenic events underlying an association. In order to extract functional information from genomic data, strategies for systematic follow-up studies on a phenotypic level are required. Here we address these limitations by applying RNA interference (RNAi) to analyze 133 candidate genes within 56 loci identified by GWAS as associated with blood lipid levels, coronary artery disease, and/or myocardial infarction for a function in regulating cholesterol levels in cells. Knockdown of a surprisingly high number (41%) of trait-associated genes affected low-density lipoprotein (LDL) internalization and/or cellular levels of free cholesterol. Our data further show that individual GWAS loci may contain more than one gene with cholesterol-regulatory functions. Using a set of secondary assays we demonstrate for a number of genes without previously known lipid-regulatory roles (e.g. CXCL12, FAM174A, PAFAH1B1, SEZ6L, TBL2, WDR12) that knockdown correlates with altered LDL-receptor levels and/or that overexpression as GFP-tagged fusion proteins inversely modifies cellular cholesterol levels. By providing strong evidence for disease-relevant functions of lipid trait-associated genes, our study demonstrates that quantitative, cell-based RNAi is a scalable strategy for a systematic, unbiased detection of functional effectors within GWAS loci.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Network analysis of sixteen genes associated with Hypertrophic Cardiomyopathy (HCM) and 31 genes asso-ciated with cardiovascular disease phenotypes in Genome Wide Association Studies (GWAS) identified three major classes of cardiovascular disease associated genes. Consistent with well-established biology, one major group comprised sar-comere genes, however, the networks further grouped the known HCM genes into subsets by muscle type. Networking generated a list of 250 candidate sarcomere associated genes for use in exploring sequence variants underlying HCM. Analysis of gene lists from three GWA studies identified two additional classes, one comprising genes associated with endothelium/smooth muscle, and a more speculative brain expressed group. Many candidate genes from GWAS loci did not fall into one of the three network classes. These analyses demonstrate the utility of network analysis in prioritization and interpretation of GWAS data, provide candidate genes for assessing sequence variants in HCM, and identifies candidate biological processes linked to cardiovascular risk in the general population.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease (CVD) is the leading cause of death in the developed world. Human genetic studies, including genome-wide sequencing and SNP-array approaches, promise to reveal disease genes and mechanisms representing new therapeutic targets. In practice, however, identification of the actual genes contributing to disease pathogenesis has lagged behind identification of associated loci, thus limiting the clinical benefits. To aid in localizing causal genes, we develop a machine learning approach, Objective Prioritization for Enhanced Novelty (OPEN), which quantitatively prioritizes gene-disease associations based on a diverse group of genomic features. This approach uses only unbiased predictive features and thus is not hampered by a preference towards previously well-characterized genes. We demonstrate success in identifying genetic determinants for CVD-related traits, including cholesterol levels, blood pressure, and conduction system and cardiomyopathy phenotypes. Using OPEN, we prioritize genes, including FLNC, for association with increased left ventricular diameter, which is a defining feature of a prevalent cardiovascular disorder, dilated cardiomyopathy or DCM. Using a zebrafish model, we experimentally validate FLNC and identify a novel FLNC splice-site mutation in a patient with severe DCM. Our approach stands to assist interpretation of large-scale genetic studies without compromising their fundamentally unbiased nature.
    Genome Biology 12/2014; 15(12):534. DOI:10.1186/s13059-014-0534-8 · 10.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The majority of compounds that enter clinical trials fail to meet regulatory standards for marketed therapeutics. Success in clinical trials is increased when therapies are directed against targets for which genetic variants have been linked to disease risk or progression in humans. Here we review how genome-wide association studies (GWAS) have furthered our understanding of the genetic basis of common disease, and how GWAS findings could stimulate development of novel drugs. Genetic screens that associate variants with clinical phenotypes of interest, like pharmacological screens that associate compounds with in vitro responses of interest, establish an intervention-response relationship on which a therapeutic hypothesis can be based. We highlight the similarities between the GWAS approach and well-established principles in early drug discovery, from primary screen through lead identification. We believe that integration of genetic and pharmacological screens will considerably enhance the development of therapeutic interventions with clear benefit to patients. Copyright © 2015. Published by Elsevier Inc.
    Biochemical Pharmacology 02/2015; 94(4). DOI:10.1016/j.bcp.2015.02.005 · 4.65 Impact Factor


Available from